跳至主要内容
临床试验/EUCTR2008-005295-27-GB
EUCTR2008-005295-27-GB进行中(未招募)不适用

A NOVEL HYBRID PROTOCOL FOR RELAPSED GERM CELL TUMOURSWITH POOR PROGNOSIS - GAMIO

Barts and The London NHS Trust0 个研究点目标入组 47 人开始时间: 2009年4月16日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
发起方
入组人数
47

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
Male

入选标准

  • 1.Germ Cell Tumour (GCT)
  • 2.Relapsed or progression on or following platinum-based chemotherapy (rising tumour markers or progressive disease on CT)
  • 3.Neutrophil count > 1.0 x109/l
  • 4.Platelets > 70 x109/l
  • 5.Haemoglobin > 100g/l (may be transfused)
  • 6.Calculated Creatinine clearance > 60mls/min or EDTA clearance of > 40ml/min
  • 7.Age 16-65 years (Patient under 35 must have a raised LDH at relapse)
  • 8.ECOG Performance status 0-3
  • 9. FDG-PET CT scans prior to chemotherapy (within 14 days of study entry).
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • 1 Other malignancy except basal cell carcinoma
  • 2Significant co-morbidity likely to make delivery of this treatment unsafe
  • 3Currently enrolled in any other investigational drug study
  • 4Unable or unwilling to give written informed consent

研究者

发起方
Barts and The London NHS Trust

相似试验